Scribe Therapeutics Inc. (SCTX) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Scribe Therapeutics Inc. (SCTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $460.2M, listed on NASDAQ, employing roughly 89 people, carrying a beta of 0.00 to the broader market. Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. Led by Benjamin L. Oakes, public since 2026-07-24.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for SCTX as of 2026-08-31; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.